

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takemoto M, Mori S, Kuzuya M, Yoshimoto S, Shimamoto A, Igarashi M, Tanaka Y, Miki T, Yokote K.	Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey.	Geriatr Geroutol int	13(2)	475-481	2013
Kitamoto T, Takemoto M, Fujimoto M, Ishikawa T, Onishi S, Okabe E, Ishibashi R, Kobayashi K, Kawamura H, Yokote K.	Sitagliptin successfully ameliorates glycemic control in werner syndrome with diabetes.	Diabetes Care	35 (12)	e83	2012
Onishi S, Takemoto M, Ishikawa T, Okabe E, Ishibashi R, He P, Kobayashi K, Fujimoto M, Kawamura H, Yokote K	Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer.	Acta diabetol	Suppl1	S259-260	2012
Okabe E, Takemoto M, Onishi S, Ishikawa T, Ishibashi R, He P, Kobayashi K, Fujimoto M, Kawamura H, Yokote K.	Incidence and characteristics of metabolic disorders and vascular complications in individuals with Werner syndrome in Japan.	J Am Geriatr Soc	60(5)	997-998	2012
大西俊一郎、竹本稔、横手幸太郎	ウェルナー症候群	日本臨牀社 別冊 先天代謝異常症候群 (第2版) 上		675-680	2012

#### IV. 研究成果の刊行物・別刷

OBSERVATIONS

**Sitagliptin Successfully Ameliorates Glycemic Control in Werner Syndrome With Diabetes**

**W**erner syndrome (WS) is an autosomal recessive disorder caused by a mutation in the *WRN* gene, and it is considered to be a representative type of progeroid syndrome (1). Patients with WS often exhibit insulin resistance, which is associated with the accumulation of visceral fat and disadipocytokemia. We and others have previously reported that pioglitazone, a peroxisome proliferator-activated receptor  $\gamma$  ligand, improved glycemic control and insulin sensitivity with normalization of disadipocytokine levels in patients with WS (2,3).

Here we describe a diabetic subject with WS that had good glycemic control with pioglitazone initially but worsened because of abdominal obesity and increasing visceral fat area. Sitagliptin, an inhibitor of dipeptidyl peptidase-4, was then administered, which resulted in successful improvement of glycemic control.

A 58-year-old Japanese woman with WS was admitted to our hospital with poor glycemic control. At the first visit to our hospital at 46 years of age, she exhibited graying and loss of hair, short stature, a hoarse voice, refractory skin ulcers, bilateral juvenile cataracts, dyslipidemia, and diabetes. The diagnosis of WS was confirmed by genomic DNA analysis. At that time, her height was 1.46 m, weight was 36 kg, and BMI was 15.1 kg/m<sup>2</sup>. Her visceral fat area was 111 cm<sup>2</sup> (normal range, <100 cm<sup>2</sup> for Japanese). She was prescribed 15 mg pioglitazone daily, which resulted in stable glycemic control. Her glycosylated hemoglobin (HbA<sub>1c</sub>) level was maintained at ~6.9% for 12 years. However, she

gradually gained weight and visceral fat area (191 cm<sup>2</sup>), which worsened her glycemic control. At the present admission, continuous glucose monitoring system (CGMS) was performed, and postprandial hyperglycemia was observed. Therefore, a 50-mg daily dose of sitagliptin was added to the pioglitazone regimen. Her laboratory parameters before and after sitagliptin administration for 6 months were as follows: fasting glucose, 122 and 110 mg/dL; 2-h postprandial glucose, 162 and 129 mg/dL; fasting C-peptide, 2.81 and 3.32 mg/dL; 2-h postprandial C-peptide, 13.99 and 11.5 mg/dL; HbA<sub>1c</sub>, 7.5 and 6.5%; and mean  $\pm$  SD of glucose levels detected by CGMS, 163.2  $\pm$  32.0 and 117.1  $\pm$  20.6 mg/dL, respectively. CGMS confirmed that sitagliptin effectively suppressed postprandial hyperglycemia.

Although patients with WS are insulin resistant, it was suggested that only those who have impaired insulin secretion develop overt diabetes (4). We were unable to observe an improvement in 2-h postprandial C-peptide levels after sitagliptin administration; nevertheless, sitagliptin may have improved early insulin secretion in response to meals. Furthermore, sitagliptin reportedly suppresses glucagon secretion. Because hyperglucagonemia has been observed in patients with WS (5), sitagliptin may ameliorate glycemic controls at least in part via correction of dysglucagonemia.

In conclusion, we demonstrated that a single dose of sitagliptin was well tolerated in a patient with WS and diabetes, resulting in a significant improvement in glycemic control. Sitagliptin may represent an alternative choice for treatment of diabetes in patients with WS. Further studies on the use of dipeptidyl peptidase-4 inhibitor in WS with diabetes will confirm our findings.

TAKUMI KITAMOTO, MD  
 MINORU TAKEMOTO, MD, PHD  
 MASAKI FUJIMOTO, MD, PHD  
 TAKAHIRO ISHIKAWA, MD  
 SHUNICHIRO ONISHI, MD  
 EMIKO OKABE, MD  
 RYOICHI ISHIBASHI, MD

KAZUKI KOBAYASHI, MD, PHD  
 HARUKIYO KAWAMURA, MD, PHD  
 KOUTARO YOKOTE, MD, PHD

From the Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan, and the Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Chiba University Hospital, Chiba, Japan.

Corresponding author: Minoru Takemoto, minoru.takemoto@faculty.chiba-u.jp.

DOI: 10.2337/dc12-1179

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

**Acknowledgments**—No potential conflicts of interest relevant to this article were reported.

T.K., T.I., S.O., E.O., R.I., K.K., and H.K. researched data. M.T. and M.F. wrote the manuscript and researched data. K.Y. contributed to the discussion and reviewed and edited the manuscript. M.T. and K.Y. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Epstein CJ, Martin GM, Schultz AL, Motulsky AG. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. *Medicine (Baltimore)* 1966;45:177–221
2. Yokote K, Hara K, Mori S, Kadowaki T, Saito Y, Goto M. Dysadipocytokemia in Werner syndrome and its recovery by treatment with pioglitazone. *Diabetes Care* 2004;27:2562–2563
3. Hattori S, Kasai M, Namatame T, Hattori Y, Kasai K. Pioglitazone treatment of insulin resistance in a patient with Werner's syndrome. *Diabetes Care* 2004;27:3021–3022
4. Yamada K, Ikegami H, Yoneda H, Miki T, Ogihara T. All patients with Werner's syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. *Diabetes Care* 1999;22:2094–2095
5. Brown DW. Werner syndrome and genetic obesity: speculation. *Med Hypotheses* 1995;45:91–93

## ACKNOWLEDGMENTS

**Conflict of Interest:** This research was supported by Korean Geriatrics Society Grants (2006). The authors have no financial disclosure or conflict of interest to report.

**Author Contributions:** Chang Won Won: study concept and design, preparation of manuscript. Hwan-Sik Hwang: acquisition of subjects and data, preparation of manuscript. Both authors approved the final version.

**Sponsor's Role:** None.

## REFERENCES

1. Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. *J Gastric Cancer* 2011;11:135-140.
2. GLOBOCAN 2008. Cancer Incidence, Mortality and Prevalence Worldwide in 2008. World Health Organization [on-line]. Available at <http://globocan.iarc.fr/> Accessed December 2011.
3. Lee J, Demissie K, Lu SE et al. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. *Cancer Control* 2007;14:78-85.
4. Hwang HS, Won CW, Lee DH. Clinical behavior of geriatricians regarding periodic screening for gastro-intestinal cancers in older adults. *J Korean Geriatr Soc* 2008;12:35-41.
5. Lee KS, Oh DK, Han MA et al. Gastric cancer screening in Korea: Report on the national cancer screening program in 2008. *Cancer Res Treat* 2011;43:83-88.

## INCIDENCE AND CHARACTERISTICS OF METABOLIC DISORDERS AND VASCULAR COMPLICATIONS IN INDIVIDUALS WITH WERNER SYNDROME IN JAPAN

*To the Editor:* Werner syndrome (WS) is an autosomal-recessive disorder caused by a mutation of the WNR gene and is considered to be a representative type of progeroid syndrome,<sup>1</sup> which is highly prevalent in Japan. Because individuals with WS often have metabolic disorders and vascular complications, a nationwide epidemiological survey was initiated in Japan to clarify the current relationship between the prevalence of metabolic disorders and vascular complications in these individuals.

The primary survey involved sending 6,000 survey sheets to hospitals with more than 200 beds. This survey

confirmed 336 new patients. The secondary survey in 2011 involved sending questionnaires to hospitals that had responded to the primary survey. Detailed clinical data were obtained for 185 cases. Complication rates of metabolic disorder and morbidity from complications in individuals with WS were compared with those in the average Japanese population.

Of the 185 patients, 86 were men, 98 were women, and the sex of one was unknown. The proportions of patients were 62.7% aged 50 to 59, 22.7% aged 40 to 49, 10.8% aged 30 to 39, 1.1% aged 20 to 29, and 0.5% aged 60 to 69, respectively. Mean height and body weight were  $158.3 \pm 8.6$  cm and  $45.3 \pm 8.3$  kg for 44 male patients and  $148.5 \pm 8.6$  cm and  $37.7 \pm 8.3$  kg for 94 female patients. The prevalence of diabetes mellitus and abnormal glucose tolerance were 55.7% and 6.5%, respectively, with a total combined rate of 62.2% (Table 1). Drugs used for diabetes mellitus included pioglitazone (10.3%), sulfonylurea (7.6%), insulin (7.0%), alpha-glucosidase inhibitor (5.9%), and metformin (4.9%). The morbidity of hyperlipidemia was 51.6%. Treatments for hyperlipidemia included statins (18.4%), fibrates (5.4%), and others (3.8%). The morbidity of hypertension was 25.9%, lower than that of the average Japanese population (Table 1). Therapeutic agents used were angiotensin II receptor antagonists (4.9%) and calcium blockers (4.3%).

Morbidities of vascular diseases in WS were 1.1% for brain hemorrhage, 2.7% for cerebral infarction, 10.3% for angina pectoris or myocardial infarction, and 17.3% for arteriosclerosis obliterans. Individuals with WS were divided into two groups (with ( $n = 45$ ) and without vascular disease ( $n = 140$ )), and correlations with diabetes mellitus ( $\chi^2 = 4.24$ ,  $P = .04$ ), hyperlipidemia ( $\chi^2 = 7.90$ ,  $P = .005$ ), and hypertension ( $\chi^2 = 11.16$ ,  $P < .001$ ) were examined, with a critical value of 3.84, confirming that metabolic disorders are closely related to vascular disease.

This study confirmed a considerably higher prevalence of metabolic disorders and cardiovascular diseases in Japanese with WS than in the average Japanese population (Table 1). Because of the high prevalence of metabolic disorders, the accumulation of visceral fat tissue in WS has been attributed to the development of the metabolic syn-

**Table 1. Morbidity from Metabolic and Atherosclerotic Diseases in Individuals with Werner Syndrome and the General Japanese Population**

Complication	Individuals with Werner Syndrome, n (%)			General Japanese Population Aged 50-59 (%)
	Total (n = 185)	Male (n = 86)	Female (n = 98)	
Diabetes mellitus	115 (62.2)	45 (69.2)	73 (61.4)	10.2*
Hypertension	48 (25.9)	17 (38.6)	31 (33.0)	47.2*
Dyslipidemia	94 (51.6)	27 (41.5)	61 (51.7)	16.4*
Low-density lipoprotein cholesterol $\geq$ 140 mg/dL	42 (22.7)	13 (29.5)	28 (28.6)	
High-density lipoprotein cholesterol $<$ 40 mg/dL	18 (9.7)	7 (15.9)	10 (10.2)	
Triglycerides $\geq$ 150 mg/dL	58 (31.4)	16 (36.4)	41 (41.8)	
Atherosclerotic diseases				
Cerebral vascular diseases	7 (3.8)	5 (5.8)	2 (2.0)	2.04†
Cardiovascular diseases	19 (10.3)	9 (10.5)	10 (10.2)	0.73†

Data from Ministry of Health, Labor, and Welfare in \*2006 and †2008.

drome,<sup>2</sup> but the mechanisms underlying the accumulation of visceral fat tissue frequently observed in WS remains largely unknown.

With regard to the characteristics of vascular disease in WS, the morbidity rate of stroke in individuals with WS was similar to that in the general Japanese population of the same age, although individuals with WS have a considerably greater prevalence of metabolic disorders. Stroke is more commonly caused by arteriolosclerosis than by atherosclerosis. Furthermore, arteriolosclerosis in the brain is associated with changes characterized by hyalinization of the tunica media or fibrinoid necrosis, which are closely associated with hypertension. The present survey demonstrated that the occurrence of hypertension as a complication of WS was lower than in the general Japanese population of the same ages; this has been a contributing factor to the smaller number of cerebral vascular disease in individuals with WS. In accordance with this lower incidence of cerebral vascular disturbances in individuals with WS, the function of the central nervous system is known to be maintained at a normal level, together with a lower incidence of dementia. Although the cause has not been clarified, the difference between the distribution of RecQ-type helicase (a protein that is mutated in WS) in vascular and cerebral blood vessels may be responsible. Furthermore, rapid cell division is associated with telomere stability, which is also associated with the WS protein.<sup>3</sup> Therefore, central nerves undergoing fewer cell divisions may be associated with a small number of disorders.

In conclusion, the frequency of stroke was lower in WS despite these individuals having numerous risk factors. A mutation in the WNR gene has been suggested as a possible protective process against the development of stroke. This finding may be significant for understanding the mechanism of the pathogenesis and progression of stroke, as well as for developing new therapeutic methods.

Emiko Okabe, MD  
 Minoru Takemoto, MD, PhD  
 Shunichiro Onishi, MD  
 Takahiro Ishikawa, MD  
 Ryouichi Ishibashi, MD

Peng He  
 Kazuki Kobayashi, MD, PhD  
 Masaki Fujimoto, MD, PhD  
 Harukiyo Kawamura, MD, PhD  
 Koutaro Yokote, MD, PhD

Department of Clinical Cell Biology and Medicine  
 Graduate School of Medicine, Chiba University  
 Chiba, Japan

## ACKNOWLEDGMENTS

This work was supported by Health and Labour Sciences Research Grants from the Ministry of Health, Labour, and Welfare of Japan for the Research on Measures for Intractable Diseases.

**Conflict of Interest:** The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.

**Author Contributions:** Emiko Okabe: analysis and interpretation of data, preparation of manuscript. Minoru Takemoto: study concept and design, analysis and interpretation of data, preparation of manuscript, acquisition of subjects and data. Shunichiro Onishi, Takahiro Ishikawa, Ryouichi Ishibashi, Peng He, Kazuki Kobayashi, Masaki Fujimoto, and Harukiyo Kawamura: acquisition of subjects and data. Koutaro Yokote: study concept and design; preparation of manuscript.

**Sponsor's Role:** None.

## REFERENCES

1. Epstein CJ, Martin GM, Schultz AL et al. Werner's syndrome: A review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. *Medicine (Baltimore)* 1966;45:177-221.
2. Yokote K, Honjo S, Kobayashi K et al. Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone. *J Am Geriatr Soc* 2004;52:1582-1583.
3. Opresko PL. Telomere ResQue and preservation roles for the Werner syndrome protein and other RecQ helicases. *Mech Ageing Dev* 2008;129:79-90.

## COMMENTS/RESPONSES

### REHABILITATION OF ELDERLY ADULTS WITH SEVERE COGNITIVE IMPAIRMENT: IT IS TIME FOR EVIDENCE

*To the Editor:* The article by Poynter and colleagues<sup>1</sup> adds important information to the growing body of literature on the rehabilitation of older adults with dementia. This topic has several important clinical, organizational, and economic implications. In recent years, an increasing number of reports have shown that the rehabilitation of this group of individuals is not only possible and feasible, but is also clinically relevant. People with dementia and hip fracture<sup>2</sup> and other nonspecific medical conditions have been successfully rehabilitated in various studies, despite the severity of their cognitive impairment.<sup>1,3</sup> Furthermore, unconventional and technology-based techniques are now promising strategies to overcome the gap of cognitive impairment in these individuals.<sup>4,5</sup>

Despite these positive remarks, motor rehabilitation of older adults with dementia is far from being an evidence-based discipline. A crucial question is the lack of randomized clinical trials, which are the only way to draw definite conclusions about the effectiveness of rehabilitation in individuals with dementia. For instance, in the field of hip fracture rehabilitation—a topic expected to become prominent in the coming years given the progressive aging of the population<sup>6</sup>—there are only two randomized clinical trials including individuals with dementia.<sup>7,8</sup> Of these, only one,<sup>8</sup> a small subgroup analysis of a previous multicompartment clinical trial to reduce postoperative delirium in elderly adults with hip fractures,<sup>9</sup> used a definition of dementia according to the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*, criteria.

The results of randomized controlled studies in individuals with dementia will provide important information to physicians and policy-makers to dedicate adequate

## Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer

Shunichiro Onishi · Minoru Takemoto · Takahiro Ishikawa · Emiko Okabe ·  
Ryoichi Ishibashi · Peng He · Kazuki Kobayashi · Masaki Fujimoto ·  
Harukiyo Kawamura · Koutaro Yokote

Received: 8 March 2012 / Accepted: 23 July 2012 / Published online: 8 August 2012  
© Springer-Verlag 2012

To the Editor

Diabetes is associated with the occurrence and progression of malignant tumors [1, 2]. Werner syndrome (WS), an autosomal recessive disorder classified as a progeroid syndrome, occurs because of mutation of the WRN gene encoding a RecQ-type DNA helicase. Because WS patients often have diabetes and malignant tumors, we initiated a nation-wide epidemiological survey in Japan to clarify the current relationship between the prevalence of diabetes and malignant tumors in them.

We sent 6921 survey sheets to hospitals with >200 beds. This survey confirmed 336 new WS patients; detailed clinical data were obtained for 163 patients with diabetes,

malignant tumors, or both [3]. These patients were categorized as diabetic ( $n = 102$ ) and non-diabetic ( $n = 61$ ). The correlation between diabetes and epithelial tumors (cancers) or non-epithelial tumors was examined using the chi-square test.

The proportions of patients grouped according to age were 1.2, 9.8, 23.3, 62.6, and 1.8 % for patients in their 20s, 30s, 40s, 50s, and 60s, respectively. The prevalence of cancers and non-epithelial tumors was 11.7 and 19.0 %, respectively. No significant difference was observed in the morbidity rates of non-epithelial tumors in diabetic or non-diabetic patients (21.6 vs. 21.3 %,  $p = 0.485$ ). However, diabetic patients showed significantly higher cancer prevalence than non-diabetic patients (16.6 vs. 4.9 %,  $p = 0.013$ ). The types of malignant tumors in these patients and their prevalence rates are shown in Table 1.

The prevalence of non-epithelial tumors and cancers is similar in WS patients [4]; non-epithelial tumors are seldom observed in the general population. Insulin resistance is related to the high cancer prevalence in diabetic patients [5]. Diabetes in WS patients is usually caused by high insulin resistance [6], which may contribute to cancer development. WS patients usually die in their 40s [4]. However, in our study, more than 60 % WS patients were in their 50s, which confirmed that the average life expectancy of Japanese WS patients has increased by 5–10 years. Because cancer incidence has increased with age, aging may be a risk factor for cancer development, especially in diabetic WS patients.

Thus, our results demonstrate that diabetic WS patients show high cancer prevalence. It is therefore important to monitor the development of not only non-epithelial tumors but also cancers in these patients, especially when WS is complicated with diabetes.

---

Communicated by Renato Lauro.

---

S. Onishi · M. Takemoto (✉) · T. Ishikawa · E. Okabe ·  
R. Ishibashi · P. He · K. Kobayashi · M. Fujimoto ·  
H. Kawamura · K. Yokote  
Department of Clinical Cell Biology and Medicine,  
Chiba University Graduate School of Medicine,  
1-8-1 Inohana, Chuo-ku, Chiba-shi,  
Chiba 260-8670, Japan  
e-mail: minoru.takemoto@faculty.chiba-u.jp

S. Onishi · M. Takemoto · T. Ishikawa · E. Okabe ·  
R. Ishibashi · K. Kobayashi · M. Fujimoto ·  
H. Kawamura · K. Yokote  
Department of Medicine, Division of Diabetes,  
Metabolism and Endocrinology, Chiba University Hospital,  
1-8-1 Inohana, Chuo-ku, Chiba-shi,  
Chiba 260-8670, Japan

**Table 1** The types of malignant tumors in a sample of 163 Japanese Werner syndrome patients with or without diabetes

		DM (n = 102)	Non-DM (n = 61)	p value
Epithelial tumors (cancers)	Thyroid cancer	3 (2.9 %) <sup>a</sup>	1 (1.6 %) <sup>b</sup>	0.013
	Pharyngeal cancer	1 (1.0 %)	0	
	Lung cancer	3 (2.9 %)	0	
	Breast cancer	1 (1.0 %)	1 (1.6 %)	
	Gastric cancer	2 (2.0 %)	0	
	Hepatic cancer	2 (2.0 %)	0	
	Pancreatic cancer	2 (2.0 %)	0	
	Renal cancer	1 (1.0 %)	0	
	Bladder cancer	0	1 (1.6 %)	
	Colon cancer	1 (1.0 %)	0	
Non-epithelial tumors	Uterus cancer	1 (1.0 %)	0	0.485
	MFH	2 (2.0 %)	4 (6.6 %)	
	Leiomyosarcoma	1 (1.0 %)	1 (1.6 %)	
	MPNST	1 (1.0 %)	0	
	Osteosarcoma	1 (1.0 %)	1 (1.6 %)	
	Melanoma	4 (3.9 %)	2 (3.3 %)	
	Meningioma	3 (2.9 %)	3 (4.9 %)	
	MDS	3 (2.9 %)	1 (1.6 %)	
	MM	2 (2.0 %)	0	
	Others	5 (4.9 %)	1 (1.6 %)	
		22 (21.6 %)	13 (21.3 %)	

The correlation between the prevalence of epithelial tumors (cancers) and non-epithelial tumors and diabetes using the chi-square test was examined

*MFH* malignant fibrous histiocytoma, *MPNST* malignant peripheral nerve sheath tumor, *MDS* myelodysplastic syndrome, *MM* multiple myeloma, *DM* diabetes mellitus

<sup>a</sup> Number (ratio among DM)

<sup>b</sup> Number (ratio among non-DM)

**Acknowledgments** This work was supported by the Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan for the Research on Measures for Intractable Diseases. No potential conflicts of interest relevant to this article were reported.

## References

- Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med* 166:1871–1877
- Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. *Acta Diabetol* 47:87–95
- Takemoto M, Mori S, Kuzuya M, Yoshimoto S, Shimamoto A, Igarashi M, Tanaka Y, Miki T, Yokote K (2012) Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey. *Geriatr Gerontol Int* (in press)
- Goto M (1997) Hierarchical deterioration of body systems in Werner's syndrome: implications for normal ageing. *Mech Ageing Dev* 98:239–254
- Simon D, Balkau B (2010) Diabetes mellitus, hyperglycaemia and cancer. *Diabetes Metab* 36:182–191
- Mori S, Murano S, Yokote K, Takemoto M, Asaumi S, Take A, Saito Y (2001) Enhanced intra-abdominal visceral fat accumulation in patients with Werner's syndrome. *Int J Obes Relat Metab Disord* 25:292–295

ORIGINAL ARTICLE: SOCIAL RESEARCH,  
PLANNING AND PRACTICE

# Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey

Minoru Takemoto,<sup>1,2</sup> Seijiro Mori,<sup>3</sup> Masafumi Kuzuya,<sup>5</sup> Shinya Yoshimoto,<sup>4</sup> Akira Shimamoto,<sup>6</sup> Masahiko Igarashi,<sup>7</sup> Yasuhito Tanaka,<sup>8</sup> Tetsuro Miki<sup>9</sup> and Koutaro Yokote<sup>1,2</sup>

<sup>1</sup>Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, <sup>2</sup>Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, <sup>3</sup>Center for Promotion of Clinical Investigation, Tokyo Metropolitan Geriatric Hospital, <sup>4</sup>Department of Plastic Surgery, Showa University, Tokyo, <sup>5</sup>Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, <sup>6</sup>Department of Cellular and Molecular Biology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, <sup>7</sup>Internal Medicine, Miyuki-Kai Hospital, Yamagata, <sup>8</sup>Department of Orthopaedic Surgery, Nara Medical University, Nara and <sup>9</sup>Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan

**Aim:** Werner syndrome (WS) is an autosomal recessive disorder of progeroid symptoms and signs. It is caused by mutations in the *WRN* gene, which encodes a RecQ DNA helicase. The aim of this study was to revise the diagnostic criteria for Japanese Werner syndrome.

**Methods:** A nationwide epidemiological study was carried out from 2009 to 2011, involving 6921 surveys sent to hospitals with more than 200 beds to assess existing WS diagnostic criteria, as well as additional signs of high incidence on the basis of clinical experience with WS.

**Results:** The existing diagnostic criteria were reviewed, and signs with >90% incidence were listed as cardinal signs. Several criteria were added, including genetic testing and calcification of the Achilles tendon, whereas criteria that are practically difficult to obtain, such as measurement of urinary hyaluronic acid, were omitted.

**Conclusion:** The 26-year-old diagnostic criteria for WS were revised on the basis of the results of a nationwide epidemiological study. The proposed revised criteria will facilitate simpler, faster and more robust diagnosis of WS in the Japanese population. *Geriatr Gerontol Int* 2013; 13: 475–481.

**Keywords:** adult progeria, diagnostic criteria, Werner syndrome.

## Introduction

Werner syndrome (WS), also known as adult progeria, is an autosomal recessive disorder caused by a mutation in the gene encoding the RecQ DNA helicase.<sup>1,2</sup> WS is characterized by early aging phenotypes including graying and loss of hair, juvenile cataracts, skin ulcers, insulin-resistant diabetes, premature atherosclerosis, and neoplasms.<sup>3</sup> The major causes of death among WS cases are malignancy and atherosclerotic vascular diseases, such as myocardial infarction.

The diagnostic guidelines of WS were released by the Research Committee on Specific Diseases-Hormone

Receptor Mechanism (Dr Etsuro Ogata, Chairman) of the Ministry of Welfare of Japan in 1984;<sup>4</sup> however, the prevalence of WS in Japan and its diagnostic criteria have not been reviewed since. Consequently, the existing criteria do not reflect the recent progress in our understanding of WS; for example, genetic tests are not included, because the WS gene was not identified until 1996.<sup>5,6</sup>

The existing criteria also list the progeroid face, cataracts and scleroderma-like skin changes as cardinal signs; however, these are relatively subjective and lack specificity. Elevation of urinary hyaluronic acid is included as an objective index, but this test is cumbersome to carry out and is not specific to WS.<sup>2,3,7</sup> In addition, some criteria, such as a decline in the proliferative potency of skin fibroblasts, are impractical in routine clinical settings.

Washington University maintains a registry of WS cases worldwide and has proposed diagnostic criteria on

Accepted for publication 3 June 2012.

Correspondence: Dr Koutaro Yokote MD PhD, Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Japan 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan. Email: kyokote@faculty.chiba-u.jp

the basis of the clinical appearance of WS in all cases (<http://www.wernersyndrome.org/>). However, most cases of WS are Japanese individuals,<sup>8</sup> and ethnicity might alter the clinical features of WS. To address this issue, we initiated a nationwide epidemiological survey from 2009 to 2011 in Japan to clarify the current clinical picture among Japanese cases of WS and revise the diagnostic criteria accordingly.

## Methods

### *Nationwide epidemiological study for WS in Japan*

A nationwide epidemiological study was carried out from 2009 to 2011 consisting of 6921 primary surveys sent to hospitals with more than 200 beds. In 2011, a secondary survey questionnaire was sent to institutions that responded to the primary survey. Respondents quantified the incidences of the signs used in the existing diagnostic criteria, as well as the incidences of additional signs that were considered valuable on the basis of their clinical experience with WS.

## Results

### *Process toward revision for new diagnostic criteria*

In 2010, 3164 responses to the primary survey had been returned, which identified 396 new WS cases. Detailed clinical data were obtained in the responses to the secondary survey (Fig. 1) for 196 of these cases, consisting of 82 men, 93 women and 18 unknown.

A total of 47 cases were confirmed both clinically and genetically, whereas 146 cases were confirmed only clinically. The proportions of WS cases by decade were 62.7%, 22.7%, 10.8%, 1.1% and 0.5% for people aged in their 60s, 50s, 40s, 30s and 20s, respectively. Mean height and bodyweight were  $158.3 \pm 8.6$  cm and  $45.3 \pm 8.3$  kg for male patients, and  $148.5 \pm 8.6$  cm and  $3.77 \pm 8.3$  kg (mean  $\pm$  SD) for female patients. Progeroid faces, bilateral cataracts, skin atrophy, clavus and callus, flat feet, bird-like faces, and abnormal voice were found in >85% of the confirmed cases of WS (Table 1).

### *Calcification in the Achilles tendon is a frequent symptom of WS*

The existing diagnostic criteria for WS include many subjective or relatively non-specific symptoms. We wished to identify criteria that are more objective and are also sensitive, and included calcification of the Achilles tendon, which is frequently observed in WS, in our survey (Fig. 2); of 72 cases in which calcification of the Achilles tendon could be determined, 80% were

positive. Furthermore, the segmental and flame-like patterns of calcification were highly specific to WS (Fig. 2).

### *New diagnostic criteria for WS*

The incidences of other symptoms among cases with or without genetic diagnosis are shown in Table 1. Some symptoms were of limited diagnostic value; for example, urinary hyaluronic acid was measured in just 14 cases, and the reference range was not specified.

On the basis of these results and with unanimous agreement from the Japanese Werner Syndrome Working Committee, new diagnostic criteria (Table 2) have been formulated on the basis of the extensive clinical experience with Japanese cases of WS accumulated over many years.

## Discussion

The diagnostic criteria for WS have been revised after an interval of 26 years on the basis of the results of a nationwide epidemiological study in Japan carried out during 2009–2011.

WS cases develop normally until their first decade and are usually first identified after the lack of an early adolescent growth spurt leading to the characteristic short stature and low bodyweight.<sup>3</sup> Both sexes are affected equally. Hair loss, graying hair, scleroderma-like skin changes, bilateral cataracts, abnormal glucose and lipid metabolism, hypogonadism, skin ulcers, and bone deformity appear by the fourth decade. Premature atherosclerosis and malignant tumors are the most common causes of death.<sup>3</sup> These symptoms appear chronologically after puberty; therefore, some symptoms might be absent in younger cases.

Progeroid faces, formerly a cardinal sign, have been changed to the more objective progeroid changes of hair (gray hair, hair loss, etc.). Regarding changes in hair, proper history taking is required, because white hair might be masked by hair dye or wigs.

Cataracts should be bilateral; in the present study, >75% of cases had bilateral cataracts. Acceptable changes of skin are atrophic skin, tight skin, clavus, callus or intractable ulcers. In WS cases, clavus and calluses might become intractable ulcers as shown in Figure 3; it is therefore important to make detailed observations of the skin lesions on the limbs for the diagnosis, as well as for aggressive treatment.

Calcification in the Achilles tendon is easily examined on routine X-ray and is highly sensitive for WS, and proactive X-ray images are recommended when WS is suspected. However, Achilles tendon calcification might not be present in young cases, and minute calcifications might require diagnosis by a specialist, such as an orthopedic surgeon.

Diagnostic criteria for Werner syndrome

<input type="checkbox"/> Case1 <input type="checkbox"/> Case2 <input type="checkbox"/> Case3 <input type="checkbox"/> Case4 <input type="checkbox"/> Case5 <input type="checkbox"/> Case6	Name: _____	
<input type="checkbox"/> Confirmed case who regularly goes to hospital. <input type="checkbox"/> Suspicious case who regularly goes to hospital. <input type="checkbox"/> Confirmed case who has been to hospital within past 5years.		
Gender <input type="checkbox"/> Male <input type="checkbox"/> Female Age <input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown		
Physical Characteristics	Presence of symptoms	Onset of symptoms
<b>1. Height and weight</b>		Height(                    )cm, Weight(                    )kg
<b>2. Progeroid face</b>		
•Gary hair and/or boldness	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
•Bird-like face	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
<b>3. Changes of feet</b>		
•Flat foot	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Clavus, Callus	<input type="checkbox"/> Yes ( <input type="checkbox"/> Upper limbs/ <input type="checkbox"/> Lower limbs) <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Deformity of foot	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Intractable skin ulcers	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>4. Changes of skin</b>		
•Atrophic skin, tight skin	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>5. Cataract</b>	<input type="checkbox"/> Yes ( <input type="checkbox"/> Hemilateral/ <input type="checkbox"/> Bilateral) <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>6. Abnormal voice (High pitched, hoarseness)</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
Signs and symptoms	Presence of symptoms	Onset of symptoms
<b>1. Consanguinity</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
<b>2. parenthood</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	Number of children (                    )
<b>3. Menopause</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>4. Abnormal glucose metabolism</b>		
•Impaired glucose tolerance	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Diabetes Mellitus	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown Medication(                    )
<b>5. Dyslipidemia</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•LDL cholesterol $\geq 140$ mg/dl	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	Medication(                    )
•HDL cholesterol $< 40$ mg/dl	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
•Triglyceride $\geq 150$ mg/dl	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
<b>6. Fatty liver</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>7. Hypertension</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown Medication(                    )
<b>8. Atherosclerotic vascular disease</b>		
•Cerebral hemorrhage	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Cerebral infarction	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Angina pectoris or myocardial infarction.	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
•Arteriosclerosis obliterans	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>9. Tumors (Including benign and/or malignant tumor)</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown Location of tumor, type of tumor (                    )
<b>10. Osteoporosis</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
<b>11. Increased urinary hyaluronic acid excretion</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	
<b>12. Genetic mutation</b>	<input type="checkbox"/> Confirmed <input type="checkbox"/> No mutations <input type="checkbox"/> Not examined	Types of mutation (                    )
<b>13. Calcification of Achilles tendon</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unkown	<input type="checkbox"/> 10s <input type="checkbox"/> 20s <input type="checkbox"/> 30s <input type="checkbox"/> 40s <input type="checkbox"/> 50s~ <input type="checkbox"/> Unknown
<b>[Memo]</b>		

**Figure 1** A secondary questionnaire for Werner syndrome (WS) patients. Of 6921 survey sheets sent to hospitals with more than 200 beds as the primary survey, we confirmed 396 new patients. As a secondary survey in 2011, we sent questionnaires to hospitals that responded to the primary survey, and we obtained detailed clinical data for 196 cases.


**Table 1** Incidence of clinical signs in genetically or clinically confirmed cases of Werner syndrome

Symptoms	Genetically confirmed ( <i>n</i> = 47)	Clinically confirmed ( <i>n</i> = 146)
Gray hair, loss of hair	97.9%	98.2%
Bird-like face	93.3%	97.2%
Skin atrophy	93.2%	99%
Skin ulcer	86.3%	88.5%
Clavus or callus	90.4%	92.4%
Flat foot	94.6%	84.3%
Cataract (bilateral)	97.8% (86.0%)	89.1% (75.5%)
Abnormality of the voice	82.2%	91.3%
Consanguinity	35.3%	40.6%
Parenthood	34.4%	34.4%
Impaired glucose tolerance	22.7%	15.1%
Diabetes mellitus	55.8%	70.5%
Hypertension	30.9%	37.0%
Dyslipidemia	85.4%	60.7%
LDL-C $\geq$ 140	50%	43.6%
HDL-C $<$ 40	17.2%	25.9%
TG $\geq$ 150	59.3%	55.9%
Fatty liver	50%	42.1%
Premature atherosclerosis		
Cerebral hemorrhage	2.5%	1.1%
Cerebral infarction	2.4%	4.4%
Coronary heart disease	11.1	16.1%
Arteriosclerosis obliterans	21.6	25.8%
Tumors	44.4	40.2%
Osteoporosis	60.7	66.4%
Calcification in the Achilles tendon	76.5	83.6%

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerol.



**Figure 2** Calcification in the Achilles tendon seen in Werner syndrome patients. (a) Segmental and (b) flame-like calcifications in the Achilles tendon are shown.



**Figure 3** Skin ulcers are typically seen in Werner syndrome patients. A skin ulcer in the left Achilles tendon is shown in a 57-year-old woman.

**Table 2** Revised diagnostic criteria for Werner syndrome

I. Cardinal signs and symptoms (onset over 10 until 40 years-of-age)	
1. Progeroid changes of hair	Gray hair, baldness, etc.
2. Cataract	Bilateral
3. Changes of skin, Intractable skin ulcers	Atrophic skin, tight skin, clavus, callus
4. Soft-tissue calcification	Achilles tendon, etc
5. Bird-like face	
6. Abnormal voice	High pitched, squeaky, hoarse voice
II. Other signs and symptoms	
1. Abnormal glucose and/or lipid metabolism	
2. Deformation and abnormality of the bone	Osteoporosis, etc
3. Malignant tumors	Non-epithelial tumors, thyroid cancer, etc
4. Parental consanguinity	
5. Premature atherosclerosis	Angina pectoris, myocardial infarction
6. Hypogonadism	
7. Short stature and low bodyweight	
III. Genetic testing	

Addendum: Mental retardation is seldom found in WS and cognitive function is often appropriate for the age. Confirmed: All cardinal signs are present or a gene mutation in addition to at least three cardinal signs. Suspected: Two or more cardinal signs or 1–2 cardinal signs in addition to other signs.


Because the incidence of bird-like faces is high (>93%), it is used as a cardinal sign. The characteristic WS face (Fig. 4) includes a pinched nasal bridge and diminished subcutaneous tissue.

The patient's voice might be high pitched, squeaky and/or hoarse; an example of the voice in a WS case is available on the committee website, with the patient's consent (<http://www.m.chiba-u.jp/class/clin-cellbiol/werner/index.html>).

Other signs and symptoms have been placed in descending order of their incidence.

Deformation and abnormality of the bone was described as osteoporosis.

Malignant tumors, which were previously only included in an addendum, are now included among the other signs and symptoms because of their high incidence and prognostic relevance. Because neoplastic lesions start developing from a young age, regular screening for malignancies is necessary for confirmed cases of WS. Epithelial and non-epithelial tumors are equally common in WS cases, in contrast to the 10:1 (epithelial : non-epithelial) ratio observed in the general



**Figure 4** A bird-like face is typically seen in Werner syndrome patients. The nasal bridge of a 57-year-old woman appears pinched, and subcutaneous tissue is diminished.

population. We recently found that cancer was significantly more prevalent in diabetic cases of WS. Therefore, routine cancer screening is especially important in this particular subgroup (Onishi *et al.* manuscript submitted). Malignancy can be treated using standard regimens, because wound healing of the trunk is normal, whereas the skin and soft tissue of the extremities tend to be atrophic and delay wound healing in WS.<sup>9</sup>

Consanguineous marriages were found in 40% of the cases, which was lower than previously reported,<sup>3</sup>

possibly because of increased movement among populations because of advances in transportation.

Diabetes is common in WS cases. Arteriosclerosis is of early-onset, and the incidence of ischemic heart disease and arteriosclerosis obliterans are particularly high. Because of the high possibility of silent myocardial ischemia, proactive and regular tests for arteriosclerosis are recommended for confirmed cases of WS. In contrast, morbidity because of stroke is similar to that seen in the general population of the same age in Japan.<sup>10</sup>

Regarding hypogonadism, it has been reported that WS is associated with secondary sexual underdevelopment, diminished fertility and testicular or ovarian atrophy. Although it was difficult to evaluate hypogonadism using the questionnaire, it is significant that less than 35% of cases in the present study had children.

On the basis of extensive clinical experience and published medical literature, cognitive function in WS cases is usually appropriate for their age, and if mental retardation is present, this is likely to be as a result of a comorbid disorder.

Genetic analysis is now included in the diagnostic criteria. *WRN* is the only gene associated with classic WS, and mutations can be identified by DNA sequence analysis<sup>5,6,11</sup> or western blotting<sup>12-14</sup> to detect aberrant forms of the protein product. Currently, these molecular genetic tests are not feasible at all institutions, and genetic testing is not essential to confirm the diagnosis of WS.

For differential diagnosis, atypical WS, which is caused by the mutation of *LMNA*;<sup>15</sup> mandibuloacral dysplasia,<sup>16</sup> which is caused by the mutation of *LMNA*;<sup>17</sup> Hutchinson-Gilford progeria syndrome, which is caused by the mutation of *LMNA*;<sup>18</sup> Rothmund-Thomson syndrome, which is caused by the mutation of *RECQ4*;<sup>19</sup> and Bloom syndrome, which is caused by the mutation of *RECQ2*,<sup>20</sup> are listed. These syndromes typically present with progeroid symptoms earlier than WS and are extremely rare in Japan.

There were some limitations to the present study. We considered the incidence of each sign in confirmed WS cases, but did not consider the incidence in the general population. Thus, the specificity of each sign has not been evaluated. Therefore, confirmed and suspected cases were specified on the basis of the results of the present study and with the consent of the Japanese Werner Syndrome Working Committee who had carried out actual clinical treatment of WS in the preceding years (Table 2).

In summary, we have revised the diagnostic criteria for WS after an interval of 26 years. We have omitted some criteria that were difficult to use in clinical settings and added criteria with more specificity, such as the calcification of the Achilles tendon, in order to make diagnosis easier and more robust. Although the genetic

basis of WS has been characterized, it remains to be determined why this defect results in the characteristic signs of WS and why these begin around puberty. The lifespan of Japanese WS cases has steadily increased by approximately 10 years.

Treatments for metabolic disorders using either HMG-CoA reductase inhibitors (statins) or peroxisome proliferator-activated receptor gamma agonists might contribute to making the prognosis of WS cases improve.<sup>21–23</sup> Therefore, it is important to diagnose WS early and begin treating the secondary metabolic disorders to prevent or minimize complications, such as premature atherosclerosis, and prolong the lifespan.

We hope that future research into WS will improve our understanding of its etiology, and that the diagnostic criteria will continue to be revised frequently to enable simpler, faster and more robust diagnosis.

## Acknowledgment

We wish to express our sincere thanks to Dr Junko Oshima, Washington University, and Dr Makoto Goto, Tooin University of Yokohama, for fruitful discussions. This work was supported by the Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan for the Research on Measures for Intractable Diseases.

## Disclosure statement

No potential conflicts of interest relevant to this article were reported.

## References

- Epstein CJ, Martin GM, Schultz AL, Motulsky AG. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. *Medicine (Baltimore)* 1966; **45**: 177–221.
- Tollefsbol TO, Cohen HJ. The effect of age on the accumulation of labile triosephosphate isomerase and thymidine incorporation in pokeweed mitogen stimulated human lymphocytes. *J Gerontol* 1984; **39**: 398–405.
- Goto M. Hierarchical deterioration of body systems in Werner's syndrome: implications for normal ageing. *Mech Ageing Dev* 1997; **98**: 239–254.
- Ogata E. Research Committee Report on specific diseases-hormone receptor mechanism, Ministry of Welfare of Japan. 1984: 13–19. (In Japanese.)
- Yu CE, Oshima J, Fu YH *et al.* Positional cloning of the Werner's syndrome gene. *Science* 1996; **272** (5259): 258–262.
- Oshima J, Yu CE, Piussan C *et al.* Homozygous and compound heterozygous mutations at the Werner syndrome locus. *Hum Mol Genet* 1996; **5**: 1909–1913.
- Tanabe M, Goto M. Elevation of serum hyaluronan level in Werner's syndrome. *Gerontology* 2001; **47** (2): 77–81.
- Matsumoto T, Imamura O, Yamabe Y *et al.* Mutation and haplotype analyses of the Werner's syndrome gene based on its genomic structure: genetic epidemiology in the Japanese population. *Hum Genet* 1997; **100** (1): 123–130.
- Ohnishi S, Fujimoto M, Oide T *et al.* Primary lung cancer associated with Werner syndrome. *Geriatr Gerontol Int* 2010; **10**: 319–323.
- Okabe E, Takemoto M, Onishi S *et al.* Incidence and characteristics of metabolic disorders and vascular complications in Werner syndrome patients in Japan. *J Am Geriatr Soc* 2012; **60**: 997–998.
- Friedrich K, Lee L, Leistriz DF *et al.* WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. *Hum Genet* 2012; **128** (1): 103–111.
- Goto M, Yamabe Y, Shiratori M *et al.* Immunological diagnosis of Werner syndrome by down-regulated and truncated gene products. *Hum Genet* 1999; **105**: 301–307.
- Shimizu T, Tateishi Y, Furuichi Y *et al.* Diagnosis of Werner syndrome by immunoblot analysis. *Clin Exp Dermatol* 2002; **27**: 157–159.
- Takada-Watanabe A, Yokote K, Takemoto M *et al.* A case of Werner syndrome without metabolic abnormality: implications for the early pathophysiology. *Geriatr Gerontol Int* 2011; **12** (1): 140–146.
- Chen L, Lee L, Kudlow BA *et al.* LMNA mutations in atypical Werner's syndrome. *Lancet* 2003; **362** (9382): 440–445.
- Cavallazzi C, Cremoncini R, Quadri A. [On a case of cleidocranial dysostosis]. *Riv Clin Pediatr* 1960; **65**: 312–326.
- Novelli G, Muchir A, Sangiuolo F *et al.* Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. *Am J Hum Genet* 2002; **71**: 426–431.
- Eriksson M, Brown WT, Gordon LB *et al.* Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. *Nature* 2003; **423** (6937): 293–298.
- Kitao S, Shimamoto A, Goto M *et al.* Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. *Nat Genet* 1999; **22** (1): 82–84.
- Ellis NA, Groden J, Ye TZ *et al.* The Bloom's syndrome gene product is homologous to RecQ helicases. *Cell* 1995; **83**: 655–666.
- Yokote K, Saito Y. Extension of the life span in patients with Werner syndrome. *J Am Geriatr Soc* 2008; **56**: 1770–1771.
- Yokote K, Hara K, Mori S, Kadowaki T, Saito Y, Goto M. Dysadipocytokinaemia in werner syndrome and its recovery by treatment with pioglitazone. *Diabetes Care* 2004; **27**: 2562–2563.
- Yasuda H, Nagata M, Hara K, Moriyama H, Yokono K. Biguanide, but not thiazolidinedione, improved insulin resistance in Werner syndrome. *J Am Geriatr Soc* 2010; **58** (1): 181–182.

## V. 參考資料

参考資料 目次

資料1 . ハッチンソン・ギルフォード・プロジェリア症候群 全国疫学調査	… 39
--------------------------------------	------

# ハッチンソン・ギルフォード・プロジェリア症候群 全国疫学調査

## 有病者数全国一次調査用紙

施設 No. <b>0001</b>
-----------------------

記載者御氏名： \_\_\_\_\_

記載年月日： 2013 年 \_\_\_\_\_ 月 \_\_\_\_\_ 日

「1. なし」もしくは、「2. あり」のどちらかに○をお付け下さい。

※「2. あり」の場合は、患者症例数をご記載下さい。

### ■ハッチンソン・ギルフォード・プロジェリア症候群「確定」患者

1. なし      2. あり      [男 \_\_\_\_\_ 例; 女 \_\_\_\_\_ 例]

### ■ハッチンソン・ギルフォード・プロジェリア症候群「疑い」患者

1. なし      2. あり      [男 \_\_\_\_\_ 例; 女 \_\_\_\_\_ 例]

### 【記入上のお願い】

1. ラミン A (LMNA) 遺伝子の異常が確定している患者さんは「確定」患者の欄に、臨床症候のみの場合は「疑い」患者の欄にご記入ください。
2. 貴診療科において、過去 10 年間に経験された症例に関してご記入下さい。
3. 全国における有病患者数の推計を行いますので、該当患者がない場合でも「1. なし」に○をつけ、ご返答下さい。
4. 症例をご経験の施設には、後日、第 2 次調査をお願いいたく存じます。その際にご協力のほどお願い申し上げます。
5. ご住所等に誤まりがございましたら、お手数ですがご訂正をお願い致します。

2013 年 2 月 28 日までに、ご返送下さいますようお願いいたします。

## こんな患者さんはいませんか？

ハッチンソン・ギルフォード・プロジェリア症候群

- ・ 低身長・低体重
- ・ 大きな頭部、カギ鼻などの小人症様の外形
- ・ 皮膚老化、脱毛、糖尿病、動脈硬化などの早老性変化が顕著



### 【 特 徴 】

- ・ 新生児期ないし幼児期（生後 6 ヶ月～ 24 ヶ月）に好発し、全身の老化が異常に進行する**早老症候群**
- ・ 非常に稀な（400 ～ 800 万人に 1 人）、散発性常染色体優性の症候群であり、ラミン A（LMNA）遺伝子の変異による。
- ・ 低身長および低体重を引き起こす成長障害がある。
- ・ 特徴的な頭蓋顔面異常（前額突出、小顎症、目の異常突出および／または小さい「くちばし状の」鼻が含まれる）がある。
- ・ 高コレステロール血症、糖尿病、骨粗鬆症、白内障、白髪などの早老変性が顕著
- ・ 動脈硬化が早期から進行し、多くの場合、13 歳頃に心筋梗塞や脳卒中によって死に至るが、成人例も報告されている。
- ・ 精神発達は正常

